OPT-IN

Ohio Psychedelic Therapy & Integration Network

OPT-IN facilitator brief · Journeys screening · October 2026

Psilocybin therapy in 2026: where things stand for Ohioans

Watch the film: Apple TV · Prime Video

Journeys (2026, directed by Christopher James Cramer) brings together 22 voices: patients, facilitators, cultivators, ethicists, lawmakers and lab technicians. They talk about trauma, depression, PTSD, end-of-life care, cost, Indigenous and legal history, and the arc of preparation, session and integration. We share the excitement the film carries: many people have found real relief, and for the first time a psilocybin treatment is in front of the FDA.

As Ohio practitioners, we hold that excitement alongside the reality that none of this is legal here yet. People in our care are already going to Oregon, Colorado and Jamaica, working with underground guides, or growing their own. We meet them where they are, with accurate information and without judgment, and we help them integrate when they come home.

The short version

  • Psilocybin and mushrooms remain Schedule I in Ohio. Possession is a felony. No Ohio city has decriminalized it, and no therapy bill has advanced.
  • The FDA has not approved psilocybin. The first application, Compass Pathways' COMP360 for treatment-resistant depression, is under rolling review and could be decided in 2027.
  • Legal access exists in Oregon and Colorado (adults 21+, no residency required), soon in New Mexico (medical), and in Jamaica, where it is unscheduled.
  • We can offer preparation, harm reduction and integration; we cannot supply, dose or refer to an illegal source.

Federal

The FDA picture

Compass Pathways' synthetic psilocybin, COMP360, met its primary endpoint in two Phase 3 trials for treatment-resistant depression. The final 26-week data came in July 2026. In April 2026 the FDA agreed to a rolling New Drug Application and awarded a Commissioner's National Priority Voucher, which can shorten review to one or two months once the filing is complete. Compass expects to finish the submission in Q4 2026 and to launch in the first half of 2027, if the FDA approves it and the DEA reschedules the drug. A White House executive order directs the DEA to move quickly on rescheduling psychedelic treatments that have completed Phase 3.

An approval would cover one pharmaceutical product, for one diagnosis, given in a certified clinical setting with monitoring. It would not make mushrooms legal, and it would not cover other uses. Other sponsors' psilocybin programs are still in trials.

Ohio

How that lands here

Today: possessing less than the bulk amount is a fifth-degree felony (up to 12 months and a $2,500 fine). Larger amounts carry more serious charges. Growing mushrooms is charged as illegal manufacture, which is a more serious felony than possession. There is no Ohio medical program, no city decriminalization, and none of the recent therapy and research bills has advanced.

After an approval: under Ohio law (R.C. 3719.43), a federal rescheduling applies to Ohio's controlled-substance schedules automatically. So an approved product could reach Ohio clinics without a new state law, through licensed prescribers and certified sites. Mushrooms and non-approved psilocybin would remain Schedule I. Counselors, social workers and other non-prescribers would most likely work in preparation, monitoring and integration roles.

The paths clients are taking

Each path carries its own protections and risks. Ask about each one without judgment; clients rarely tell us about something they expect to be shamed for.

Oregon

Licensed · since 2023

State-licensed service centers with trained facilitators. No diagnosis or residency required. Clients take psilocybin on site and leave with none.

Know: roughly $1,500–$3,500 for a full package. Many centers have closed under high costs and license fees, so confirm the center is open before booking travel.

Colorado

Licensed · since 2025

Licensed healing centers, including a lower-cost "micro" tier, open to adults 21+ with no residency requirement. Personal use is also decriminalized for adults there.

Know: programs run about $1,500 to $9,500 and insurance doesn't cover them. Nothing is legal to bring back across state lines.

New Mexico

Medical · launching

The state's medical psilocybin program is aiming for its first patients by December 2026, for qualifying conditions such as treatment-resistant depression, PTSD, substance use disorders and end-of-life distress.

Know: the rules, including who is eligible, are still being finalized. Check nmhealth.org.

Jamaica & abroad

Unscheduled · unregulated

Psilocybin mushrooms are not scheduled in Jamaica, and a retreat industry has grown there. Quality ranges from medically staffed to nothing at all.

Know: ask about medical screening, staff training, the ratio of staff to guests, and the emergency plan. Never travel home with it.

Underground guides

Unlicensed · in Ohio

Some guides are skilled and caring, and there is still no license, complaint process or oversight.

Know: help clients ask about screening, consent and touch boundaries, what's in the dose, who else is present, and what happens in a medical or psychiatric emergency.

Growing & self-dosing

Felony in Ohio

Many people grow and dose privately, and potency varies a lot from batch to batch and from one mushroom to the next.

Know: no one should dose alone. A sober sitter, a low first dose and a plan for the hours after all help, and cultivation carries real legal exposure.

Any route

Harm-reduction essentials

  • Screening: a personal or family history of psychosis or bipolar disorder, heart conditions, pregnancy, and current crisis all change the risk.
  • Medications: lithium is linked to seizures with psychedelics. Tramadol and MAOIs need review. SSRIs and other antidepressants can blunt the effects. Clients shouldn't stop medication without their prescriber.
  • What's in it: store-bought "mushroom" gummies and chocolates have contained other substances; in 2024 the FDA tied one brand to more than 100 illnesses. Whole, identified mushrooms or a licensed source are safer, and test kits exist.
  • Set and setting: a sober sitter, a safe space, no driving, and time cleared afterward.
  • Integration: the weeks after a session are where change takes root, and that is where our work comes in.

Fireside Project (free peer support, during or after): 62-FIRESIDE (623-473-7433)

Medical emergency: 911 · Crisis: 988

For Ohio clinicians

Staying inside our scope

  • Can: educate, explore a client's plans, offer harm-reduction information, help them prepare, and do integration afterward.
  • Can't: supply, procure, handle or dose psilocybin, attend an illegal session, or refer to a specific underground provider.
  • Document the conversation as harm reduction and informed consent, including the legal risks the client has been told about.
  • When unsure, consult your licensing board's guidance, your ethics code and a colleague. This brief is education, not legal advice.

After the film

Questions for the room

  1. Which story in Journeys stayed with you, and why?
  2. The film shows preparation, session and integration. Which of those is hardest to find in Ohio right now?
  3. If an FDA-approved option arrives in 2027, who is still left out by cost, diagnosis or access?

Prepared by OPT-IN, the Ohio Psychedelic Therapy & Integration Network, for the Journeys community screening. Current as of October 23, 2026. Educational only: not medical or legal advice, and not an endorsement of illegal use. Laws and timelines change quickly.

Sources: Journeys (Apple TV, 2026); Compass Pathways, Q2 2026 results (Aug. 5, 2026); Ohio R.C. 2925.11; Ohio R.C. 3719.43; Oregon Health Authority, Access Psilocybin Services; Colorado Natural Medicine Division; Colorado Natural Medicine FAQ; New Mexico Medical Psilocybin Program; Harris Sliwoski, Psychedelic Law Blog (Jamaica); FDA, Diamond Shruumz investigation (2024); Fireside Project; 988 Lifeline.